Loading stock data…
RYTM
$87.86+1.93 (+2.25%)
After Hours$87.86+0.00 (+0.00%)· Last close Jun 9
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rhythm Pharmaceuticals, Inc. in the Healthcare sector is trading at $87.86 with a market capitalization of $5.8B. Wall Street consensus targets $138.20 (15 analysts), implying a +57.3% move over the next 12 months. The stock is currently 28% below its 52-week high of $122.20, remaining 10.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +57.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$87.86
Potential Downside
0%
Whystock Fair Value$87.86
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$138.20+57.3%
Range$105.00 – $159.00
Fundamentals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.81B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-85.30%
Volume
Today's trading volume
582,129
Recent News
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Updating Its Bardet-Biedl Diagnosis Algorithm
Rhythm Pharmaceuticals recently announced the publication of an updated, evidence-based diagnostic algorithm for Bardet-Biedl syndrome in the American Journal of Medical Genetics, aiming to help clinicians reach faster, clinically grounded diagnoses supported by modern genetic testing. By simplifying recognition of this complex, multi-organ rare disease across age groups and specialties, the new algorithm could expand identification of eligible patients and deepen Rhythm’s connections with...
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Shareholders of Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) will be pleased this week, given that the stock price is...
Rhythm Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Rhythm Pharmaceuticals, Inc.'s Q1 2026 earnings call
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday
It released an encouraging quarterly earnings report and business update before market open.
Rhythm Pharmaceuticals Q1 Earnings Call Highlights
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported first-quarter 2026 revenue growth as the company began its U.S. commercial launch of IMCIVREE for acquired hypothalamic obesity (HO) and highlighted new regulatory progress in Europe and Japan. First-quarter results show continued IMCIVREE growth Chair